PAN Provides Co-payment Assistance for Patients with Secondary Hyperparathyroidism (SHPT)
WASHINGTON, D.C., November 1, 2011– Patient Access Network (PAN) Foundation is pleased to announce that it has begun providing co-payment assistance to underinsured patients with secondary hyperparathyroidism (SHPT) who are receiving dialysis treatment. Qualified patients will be granted up to $4,000 per year to cover out-of-pocket expenses associated with their treatment. Patients who earn up to 400% of the Federal Poverty Level, or $58,840 for a family of two, are eligible for assistance.
"We know that many patients aren't able to begin or continue therapy because of high out-of-pocket costs, " said Pat McKercher, President of Patient Access Network Foundation. "PAN is pleased to begin a new partnership in providing SHPT patients generous assistance so they can access their needed medications and focus on getting better."
Secondary hyperparathyroidism (SHPT) is when the parathyroid glands in your neck produce too much parathyroid hormone (PTH) because your calcium levels are too low. When calcium levels are too low, the body responds by increasing production of parathyroid hormone. This increase in parathyroid hormone causes more calcium to be taken from the bone and more calcium to be reabsorbed by the intestines and kidney. Kidney failure is a common cause of secondary hyperparathyroidism.
This new fund is an expansion of PAN’s 34 existing disease funds that cover conditions such as multiple myeloma, colorectal cancer, and rheumatoid arthritis. PAN provides grants of $1,500 to $15,000 per year to qualified patients to help pay for medications for these diseases. Since 2004, PAN has provided more than $173 million in assistance for out-of-pocket expenses to more than 125,000 patients in need. For more information about the Patient Access Network Foundation, visit www.PANfoundation.org.